Description
THIS IS FOR THE PURCHASE AND DELIVERY OF PYLARIFY.
First action · last action
2023-12-21 · 2025-06-10
Transactions
2
First transaction's obligation
$1,623,924
Base + all options value (sum of deltas)
$1,104,268
Extent competed
COMPETED UNDER SAP
Other than full & open authority
—
Set-aside
SMALL BUSINESS SET ASIDE - TOTAL
Offers received
2
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-12-21+$1,623,924= $1,623,924
- Mod P000012025-06-10-$519,656= $1,104,268
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-12-21 | +$1,623,924 | $1,623,924 | THIS IS FOR THE PURCHASE AND DELIVERY OF PYLARIFY. |
| Mod P00001· FUNDING ONLY ACTION | 2025-06-10 | −$519,656 | $1,104,268 | THIS IS FOR THE PURCHASE AND DELIVERY OF PYLARIFY. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI JV1AHJHGUGG3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25526N0392 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS | $357,066 | FY2026 |
| 36C25526N0245 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6505 · DRUGS AND BIOLOGICALS | $1,172,834 | FY2026 |
| 36C24226N0463 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $624,017 | FY2026 |
| 36C24226N0388 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $830,796 | FY2026 |
| 36C24226D0040 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C25026P0310 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $347,000 | FY2026 |
Other recipients under 6505 from 245-NETWORK CONTRACT OFFICE 5 (36C245) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24526N0840 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $19,139 | FY2026 |
| 36C24526N0839 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $38,360 | FY2026 |
| 36C24526N0837 | QOL MEDICAL LLC | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $16,945 | FY2026 |
| 36C24526N0835 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $34,605 | FY2026 |
| 36C24526N0834 | GALDERMA LABORATORIES, L.P. | 245-NETWORK CONTRACT OFFICE 5 (36C245) | $16,960 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24524P0232_3600_-NONE-_-NONE- · retrieved 2026-09-26.